BAR 502 free base · Synonyms: BAR-502 · BAR502

BAR502 is a dual FXR and GPBAR1 agonist.

For research use only. Not for human or veterinary use.

Target G protein-coupled Bile Acid Receptor 1 FXR Autophagy

Research area Neurological Disease Inflammation/Immunology

Purity >98% Stock Inquire

Data Sheet SDS COA

BAR 502 structure

CAS No.: 1612191-86-2

Download structure (.mol)

Pack sizes & pricing

Size	Price	SKU	Stock
250 mg	USD 450.00	BP-01905-250mg	In stock	Get quote
500 mg	USD 720.00	BP-01905-500mg	In stock	Get quote
1 g	USD 1,080.00	BP-01905-1g	In stock	Get quote
5 g	Inquire	BP-01905-5g	Inquire	Inquire

Need another size or custom synthesis? Request a quote.

Description

BAR502 is a dual FXR and GPBAR1 agonist with IC50 values of 2 μM and 0.4 μM, respectively.

Biological activity

In Vitro BAR502 is a truncated side chain alcohol with both substituents on ring B in α-configuration. At the concentration of 10 μM, BAR502 fails to transactivate GR, PPARγ, and LXR, respectively, but it transactivates the nuclear receptor PXR. BAR502 is able to induce the expression of pro-glucagon mRNA in GLUTAg cells, an intestinal endocrine cell line, as well as to increase cAMP concentrations in THP-1 cells. BAR502 induces the expression of OSTα, BSEP, and SHP in HepG2 cells. BAR502 shows a very potent activity in the recruitment of SRC-1 coactivator and high affinity to FXR. In Vivo Treatment with BAR502 causes a 10% reduction of b.w., increases insulin sensitivity and circulating levels of HDL, while reduces steatosis, inflammatory and fibrosis scores and liver expression of SREPB1c, FAS, PPARγ, CD36 and CYP7A1 mRNA. BAR502 increases the expression of SHP and ABCG5 in the liver and SHP, FGF15 and GLP1 in intestine. BAR502 promotes the browning of epWAT and reduces liver fibrosis induced by CCl4. In models of non-obstructive cholestasis, BAR502 attenuates liver injury without causing itching. Co-treatment with BAR502 increases survival, attenuates serum alkaline phosphatase levels and robustly modulates the liver expression of canonical FXR target genes including OSTα, BSEP, SHP and MDR1, without inducing pruritus.

Identifiers

SMILES: CCC1C(O)[C@H]2[C@@H]3CC[C@H](C(C)CCO)[C@@]3(C)CC[C@H]2[C@@]2(C)CCC(O)C[C@@H]12
InChIKey: HYCMOIGNYNCMRH-BNVZFTBUSA-N

Specifications

MW (average): 392.6151
Formula: C₂₅H₄₄O₃
CAS No.: 1612191-86-2
Physical state: Solid
Color: White to off-white
Shipping: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage: Powder -20℃ 2 years; In solvent -20℃ 1 month;

Solubility

Soluble in DMF/ethanol

Documents

References

[1]. Festa C, et al. Exploitation of cholane scaffold for the discovery of potent and selective farnesoid X receptor (FXR) and G-protein coupled bile acid receptor 1 (GP-BAR1) ligands. J Med Chem. 2014 Oct 23;57(20):8477-95.

[2]. Carino A, et al. BAR502, a dual FXR and GPBAR1 agonist, promotes browning of white adipose tissue and reverses liver steatosis and fibrosis. Sci Rep. 2017 Feb 16;7:42801.

[3]. Cipriani S, et al. Impaired Itching Perception in Murine Models of Cholestasis Is Supported by Dysregulation of GPBAR1 Signaling. PLoS One. 2015 Jul 15;10(7):e0129866.

Same target

Search G protein-coupled Bile Acid Receptor 1

Same research area

Search Neurological Disease